BSE filing, NSE: MARKSANS. Summary written from the filing by ALFA Finder's alert engine.
Marksans Pharma Ltd: key numbers
- Share price
- ₹303.70
- Market cap
- ₹13,764 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 24.6×Sector 43.0×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Earnings Call Transcript: Key Takeaways
Headline growth is strong: revenue up 30.5% to ₹940 Cr and EBITDA margin 22.8%, above the 21–22% guide. Sequentially, margin, gross margin and PAT all fell, and growth is partly acquired.
Marksans Pharma Employee Stock Options
Marksans Pharma allotted 56,250 equity shares to employee stock option grantees under its 2024 scheme. Shares were issued on exercise of vested options.
Marksans Pharma Results Update
Marksans Pharma reported Q2FY27 revenue of ₹940 crore and H1FY27 PAT of ₹303 crore. EBITDA grew 48% to a record ₹214 crore in the quarter.
Marksans Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹940cr (+30.5% YoY), EBITDA ₹214cr at 22.8% margin (+274bps), PAT ₹143.5cr (+44.8%). H1 PAT ₹303cr; net cash ₹1,095cr; Europe front-end being built.
Marksans Pharma Q2 FY27 Results: Net Profit ₹143.5 Cr, Up 44.8% YoY
Marksans Pharma Ltd reported revenue from operations of ₹940.2 Cr (+30.5% YoY) and net profit of ₹143.5 Cr (+44.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹143.5 Cr · +44.8% YoY
Marksans Pharma Board Meeting Date
Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.
Other business update announcements
All →Religare Enterprises Business Update
Religare Finvest, a material subsidiary, resumed lending after RBI lifted its Corrective Action Plan. It disbursed its first Loan Against Property on 6 November 2026.
Purple Wave Infocom Business Update
Purple Wave signed a 5-year data integration agreement with BPCL for its Hygiair devices. The Rs 10 crore figure is indicative, not firm order value.
- Execution
- 5 years
Msafe Equipments Business Update
MSAFE Equipments announced a Dhanteras puja at its upcoming Mathura integrated manufacturing facility, expected to commence operations by May 2027. The release describes planned capacity expansion but reports no contract, order, or financial value.
Skyways Air Services Business Update
Skyways Air Services renewed its Global Annual Agreement with Qatar Airways for one year. The agreement's size is not quantifiable, so no value is assigned.
- From
- Qatar Airways Group Q.C.S.C.
- Execution
- 1 year from effective date 1 January 2026
Zydus Lifesciences Business Update
Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.
Rajshree Sugars & Chemicals Business Update
Rajshree Sugars reported October 2026 operational data for its three sugar units. Sugar sales were 17,849 MT, with no cane crushed during the month.